Bio Pharmaceuticals and Biomedicine Market By Type (Biologics, Biosimilars, Vaccines, Gene Therapies, Cell Therapies), By Application (Oncology, Neurology, Cardiovascular, Autoimmune Diseases, Infectious Diseases), By Form (Injectable, Oral, Topical), By End-Use (Hospitals, Clinics, Pharmaceutical & Biotech Companies), and By Region; Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Bio Pharmaceuticals and Biomedicine Market was valued at USD 378.6 billion in 2023 and will surpass USD 649.5 billion by 2030; growing at a CAGR of 8.0% during 2024 - 2030.

The bio-pharmaceuticals and biomedicine market has experienced significant growth, driven by advancements in biotechnology, the increasing prevalence of chronic diseases, and the rise of biologic treatments. This market includes a wide range of therapeutic products, such as biologics, biosimilars, vaccines, gene therapies, and cell therapies, each offering targeted and personalized treatments. The shift towards biologics, which often provide more effective solutions for diseases that were previously hard to treat, has contributed to the market's rapid expansion. Biomedicine, which integrates biological sciences with medicine, plays a crucial role in developing these innovative treatments and improving patient outcomes.

The rising incidence of conditions such as cancer, autoimmune diseases, and cardiovascular disorders has further fueled demand for advanced biologic therapies. Gene and cell therapies, in particular, are being hailed as promising future treatments for genetic disorders and certain types of cancers. With continuous research and development, this market is poised to grow, offering new and effective treatment options. In addition, regulatory approvals and the commercialization of new biologics and biosimilars are helping to increase access to these therapies, which are becoming an integral part of modern healthcare.

Biologics Segment Is Largest Owing to Their Efficacy in Treating Complex Diseases

The biologics segment holds the largest share in the bio-pharmaceuticals and biomedicine market, primarily due to their efficacy in treating complex and chronic diseases such as cancer, autoimmune disorders, and genetic conditions. Biologics, which are derived from living organisms, offer targeted therapies that can be more effective than traditional small-molecule drugs, especially for conditions that require personalized medicine. The use of biologics in oncology, neurology, and immunology is particularly significant, as they provide new treatment options for conditions with limited therapeutic alternatives.

The market for biologics continues to expand, with new innovations in monoclonal antibodies, recombinant proteins, and gene-modifying treatments. These therapies are transforming the way diseases are treated, offering higher success rates and fewer side effects compared to conventional treatments. As research in biologics advances, new applications are emerging, and the demand for these therapies is expected to grow, maintaining the biologics segment as the dominant force in the market.

Oncology Application Dominates Due to Rising Cancer Prevalence

The oncology application is the largest and most lucrative segment within the bio-pharmaceuticals and biomedicine market. Cancer is one of the leading causes of death globally, with an increasing number of cases and a growing aging population, which has contributed to the rising demand for advanced cancer treatments. Biologics, especially monoclonal antibodies and immune checkpoint inhibitors, have become essential in cancer treatment, offering more precise and effective therapies compared to traditional chemotherapy.

The focus on personalized oncology, which tailors treatment based on the genetic makeup of the patient and their tumor, is driving the demand for biologic therapies in this field. With continuous research, the development of immunotherapies and targeted treatments has revolutionized cancer care, increasing the success rates of treatment and extending survival for many patients. The oncology application is expected to continue to dominate the market as new biologic therapies emerge and become available for a wider range of cancer types.

Injectable Form Is Largest Due to Biologics Delivery Methods

The injectable form is the most common and largest segment in the bio-pharmaceuticals and biomedicine market, particularly in the biologics and vaccines sectors. Many biologic therapies, such as monoclonal antibodies, gene therapies, and vaccines, are delivered through injections because they are large, complex molecules that cannot be taken orally due to digestive breakdown. Injectable formulations allow for direct delivery into the bloodstream, ensuring that the biologic agent reaches the intended site of action effectively.

The growing use of self-administered injectable drugs has also contributed to the dominance of this form. Innovations in device technology, such as auto-injectors and pre-filled syringes, have made it easier for patients to manage their treatments at home, reducing the need for hospital visits. As the demand for biologics continues to rise, the injectable form will maintain its prominence as the preferred delivery method for many bio-pharmaceutical and biomedicine products.

Hospitals End-Use Segment Is Largest Due to High Patient Volume

The hospitals end-use segment is the largest in the bio-pharmaceuticals and biomedicine market, driven by the high volume of patients requiring advanced biologic therapies, particularly for complex diseases like cancer and autoimmune conditions. Hospitals are often the primary centers for administering biologic treatments, especially injectable therapies, which require trained healthcare professionals for proper handling and administration.

The demand for biologics in hospitals has been further accelerated by the increasing prevalence of chronic diseases and the growing number of patients seeking advanced treatment options. As hospitals continue to serve as the primary providers of specialized care, they will remain the largest end-use segment in the bio-pharmaceuticals and biomedicine market. Additionally, the expansion of hospital infrastructure, particularly in emerging markets, will continue to drive the demand for biologic treatments.

North America Is Largest Market Due to Advanced Healthcare System

North America is the largest market for bio-pharmaceuticals and biomedicine, primarily due to its advanced healthcare system, high prevalence of chronic diseases, and leading pharmaceutical research and development capabilities. The United States, in particular, dominates the market, with its well-established pharmaceutical industry and the highest number of biologic drug approvals globally. The strong presence of major biopharmaceutical companies, along with extensive healthcare infrastructure, contributes to North America's leadership in the bio-pharmaceuticals and biomedicine market.

The growing adoption of advanced therapies, including gene therapies and cell therapies, further bolsters the region's position in the market. As new biologic treatments are introduced, North America remains at the forefront of their commercialization, supported by favorable regulatory environments and substantial healthcare spending. The region is expected to maintain its dominance in the market, driven by continued innovation and increasing demand for personalized medicine.

Competitive Landscape

The bio-pharmaceuticals and biomedicine market is highly competitive, with several key players leading the development and commercialization of innovative therapies. Major companies in this market include Amgen, Roche, Johnson & Johnson, Pfizer, and Merck, each of which has a strong portfolio of biologics, vaccines, and biosimilars. These companies invest heavily in research and development to advance new treatments, particularly in oncology, neurology, and autoimmune diseases.

In addition to the global leaders, there is a growing presence of specialized biotech companies focusing on niche areas, such as gene therapies and personalized medicine. The competition in the market is also influenced by partnerships, collaborations, and acquisitions, as companies seek to expand their product pipelines and enhance their technological capabilities. The emergence of biosimilars is also reshaping the competitive landscape, providing more affordable alternatives to branded biologics and increasing market access for patients. The continuous evolution of the bio-pharmaceuticals and biomedicine sector will keep the competitive dynamics fluid, with ongoing innovation and regulatory developments shaping the future of the market.

Recent Developments:

• In November 2024, Amgen Inc. announced the successful launch of a new biosimilar biologic for the treatment of cancer.
• In October 2024, Roche Holding AG introduced an innovative gene therapy aimed at treating inherited retinal diseases.
• In September 2024, Pfizer Inc. unveiled a new vaccine for an infectious disease, developed using cutting-edge biomedicine technologies.
• In August 2024, Merck & Co., Inc. expanded its biopharmaceutical portfolio with the release of a new cell therapy for oncology patients.
• In July 2024, Johnson & Johnson entered into a partnership with biotech firms to accelerate the development of gene therapies for neurological disorders.

List of Leading Companies:

• Amgen Inc.
• Roche Holding AG
• Johnson & Johnson
• Novartis International AG
• Pfizer Inc.
• Merck & Co., Inc.
• Eli Lilly and Company
• Gilead Sciences, Inc.
• Bristol-Myers Squibb
• Sanofi S.A.
• AstraZeneca plc
• GlaxoSmithKline plc
• Biogen Inc.
• Regeneron Pharmaceuticals
• AbbVie Inc.

Report Scope: